You are here: Industry Insights > Osteoporosis

News List

osteolabs Publishes First Real-World Evidence Data from Close to 3, 000 OsteoTest Patient Samples Biotech Newswire
August 16, 2024
osteolabs GmbH announced the publication of real-world evidence data from close to 3,000 OsteoTest patient samples in the prestigious journal Bone.
Osteolabs to Present New Clinical Data from Over 2.400 OsteoTest Routine Samples at the WCO-IOF-ESCEO Congress PharmaSources
April 10, 2024
New data fully supporting potential for OsteoTest to qualify as new universal diagnostic method for early osteoporosis risk assessment and therapeutic control.
Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody TST002 prnasia
July 07, 2021
Transcenta Holding Limited announces that NMPA has accepted IND application of its anti-sclerostin monoclonal antibody TST002.
Drug doubles down on bone cancer, metastasis worldpharmanews
June 24, 2021
Bone cancer is hard to treat and prone to metastasis. Research teams at Rice University and Baylor College of Medicine have a new strategy to attack it.
Osteoporosis drug may halve repeat hip replacement procedures: Study expresspharma
January 15, 2021
Researchers from the University of Sheffield and Sheffield Teaching Hospitals found the osteoporosis drug, denosumab, could protect patients from osteolysis, reduce the need for re-operations, and reduce the health burden of this disease.
Haoma Medica Completes First-in-Human Trial for Osteoporosis Treatment americanpharmaceuticalreview
December 14, 2020
Haoma Medica announced the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.
Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis prnasia
November 27, 2020
Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.
Common osteoporosis treatments could reduce incidence of COVID-19 europeanpharmaceuticalreview
November 06, 2020
Osteoporosis treatments including denosumab, zoledronate and calcium could protect patients against COVID-19, researchers have said.
One broken bone leads to another, warns IOF on World Osteoporosis Day prnasia
October 22, 2020
Today, the International Osteoporosis Foundation (IOF) calls for all adults to be alert to their risk factors for osteoporosis, a disease which can lead to a dangerous, life-threatening spiral of broken bones.
Using rafts to enhance bioavailability of ibandronate europeanpharmaceuticalreview
October 16, 2020
Researchers have developed a novel tablet formulation of ibandronate which increases the oral bioavailability of the drug by releasing it from a hydrogel raft formed in the stomach.

Previous page 1 2 3 4 Next page